CoChat

Monitoring patients treated with anti-TNF- biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies

Svenson, M., Geborek, P., Saxne, T., Bendtzen, K. · 2007 · Rheumatology

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

OBJECTIVES: Infliximab is an anti-tumour necrosis factor-alpha (TNF-alpha) mouse-human IgG1/kappa antibody used to treat patients with rheumatoid arthritis (RA) and other inflammatory diseases. Unfortunately, response failure and side-effects due to immunogenicity of the drug are not rare. In this study, we have compared different methods of assessing drug levels and anti-infliximab antibodies (Abs) and analysed the character of these Abs in sera of RA patients treated with infliximab for 1.5-18 months. METHODS: Functional serum infliximab levels and anti-infliximab Abs were measured by fluid-phase RIAs using 125I-labelled ligands in combination with molecular size and affinity chromatography, and immune complex precipitation. RESULTS: Anti-infliximab Abs were predominantly IgG, 36% being IgG4, and half the immune complexes were lambda-light-chain-positive. Ab titres were associated with inhibition of TNF binding to the drug, and low trough levels of infliximab were most frequent in anti-infliximab Ab-positive sera. Cross-binding to two other anti-TNF drugs was not observed. Detection of anti-infliximab Abs by solid-phase RIA using cross-binding of plastic-fixed and soluble infliximab exhibited low sensitivity and the data were inconsistent with results obtained from binding of the Abs to soluble infliximab. CONCLUSIONS: Specific and neutralizing anti-infliximab antibodies develop in RA patients treated with infliximab, and that low trough levels of functional infliximab are associated with the presence of such antibodies. The most sensitive antibody assay involved binding to soluble and intact infliximab. Assessments of bioavailability and immunogenicity of anti-TNF biologicals may be used to optimize dose regimens and prevent prolonged use of inadequate therapy.

Overview

Integrity signals

Registry

Crossref · 10.1093/rheumatology/kem261

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 29 references

Cited by

See all 195

Metadata

Authors
Svenson, M., Geborek, P., Saxne, T., & Bendtzen, K.
Affiliations
  • Rigshospitalet (DK)
  • Lund University (SE)
Venue
Rheumatology
Published
2007-08-05
Volume
46
Issue
12
Pages
1828-1834
ISSN
  • 1462-0324 (ISSN-L)
  • 1462-0332
OpenAlex
W2122735365
Cited by
189
References
29
Citations by year
2025: 3 · 2024: 4 · 2023: 2 · 2022: 3 · 2021: 2 · 2020: 5 · 2019: 8 · 2018: 7 · 2017: 10 · 2016: 8 · 2015: 18 · 2014: 22 · 2013: 16 · 2012: 25
FWCI
4.09
Type
journal article
Language
en
Open access
closed
Locations
  • Lara D. Veeken (publishedVersion)
  • PubMed (publishedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords
infliximab, anti-infliximab antibodies, drug immunogenicity, rheumatoid arthritis, drug monitoring, trough concentration, neutralizing antibodies, IgG4, lambda light chain, immune complexes, solid-phase radioimmunoassay, bioavailability, dose optimization
MeSH terms
Infliximab, Adult, Aged, Antibodies, Anti-Idiotypic, Antibodies, Monoclonal, Arthritis, Rheumatoid, Biological Availability, Dose-Response Relationship, Drug, Drug Administration Schedule, Enzyme-Linked Immunosorbent Assay, Female, Humans, Immunoglobulin G, Male, Middle Aged, Monitoring, Physiologic, Radioimmunoassay, Sensitivity and Specificity, Cohort Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Monitoring patients treated with anti-TNF- biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. https://app.cochat.ai/papers/10.1093/rheumatology/kem261
The paper
Svenson, M., Geborek, P., Saxne, T., & Bendtzen, K. (2007). Monitoring patients treated with anti-TNF- biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology. https://doi.org/10.1093/rheumatology/kem261

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.